These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 29907810)

  • 1. ASXL1/EZH2 mutations promote clonal expansion of neoplastic HSC and impair erythropoiesis in PMF.
    Triviai I; Zeschke S; Rentel J; Spanakis M; Scherer T; Gabdoulline R; Panagiota V; Thol F; Heuser M; Stocking C; Kröger N
    Leukemia; 2019 Jan; 33(1):99-109. PubMed ID: 29907810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clonal evolution revealed by whole genome sequencing in a case of primary myelofibrosis transformed to secondary acute myeloid leukemia.
    Engle EK; Fisher DA; Miller CA; McLellan MD; Fulton RS; Moore DM; Wilson RK; Ley TJ; Oh ST
    Leukemia; 2015 Apr; 29(4):869-76. PubMed ID: 25252869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The loss of Ezh2 drives the pathogenesis of myelofibrosis and sensitizes tumor-initiating cells to bromodomain inhibition.
    Sashida G; Wang C; Tomioka T; Oshima M; Aoyama K; Kanai A; Mochizuki-Kashio M; Harada H; Shimoda K; Iwama A
    J Exp Med; 2016 Jul; 213(8):1459-77. PubMed ID: 27401345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD133 marks a stem cell population that drives human primary myelofibrosis.
    Triviai I; Stübig T; Niebuhr B; Hussein K; Tsiftsoglou A; Fehse B; Stocking C; Kröger N
    Haematologica; 2015 Jun; 100(6):768-79. PubMed ID: 25724578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for MPL W515L/K mutations in hematopoietic stem cells in primitive myelofibrosis.
    Chaligné R; James C; Tonetti C; Besancenot R; Le Couédic JP; Fava F; Mazurier F; Godin I; Maloum K; Larbret F; Lécluse Y; Vainchenker W; Giraudier S
    Blood; 2007 Nov; 110(10):3735-43. PubMed ID: 17709604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The role of driver and subclonal mutations in pathogenesis of primary myelofibrosis].
    Mózes R; Gángó A; Boha Z; Csomor J; Bödör C
    Magy Onkol; 2017 Mar; 61(1):36-45. PubMed ID: 28273187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells.
    Wang X; Zhang W; Tripodi J; Lu M; Xu M; Najfeld V; Li Y; Hoffman R
    Blood; 2010 Dec; 116(26):5972-82. PubMed ID: 20858855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leukemic transformation driven by an ASXL1 mutation after a JAK2V617F-positive primary myelofibrosis: clonal evolution and hierarchy revealed by next-generation sequencing.
    Ferrer-Marín F; Bellosillo B; Martínez-Avilés L; Soler G; Carbonell P; Luengo-Gil G; Caparrós E; Torregrosa JM; Besses C; Vicente V
    J Hematol Oncol; 2013 Sep; 6():68. PubMed ID: 24011025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis.
    Guglielmelli P; Pacilli A; Rotunno G; Rumi E; Rosti V; Delaini F; Maffioli M; Fanelli T; Pancrazzi A; Pietra D; Salmoiraghi S; Mannarelli C; Franci A; Paoli C; Rambaldi A; Passamonti F; Barosi G; Barbui T; Cazzola M; Vannucchi AM;
    Blood; 2017 Jun; 129(24):3227-3236. PubMed ID: 28351937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
    Tefferi A
    Am J Hematol; 2013 Feb; 88(2):141-50. PubMed ID: 23349007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells.
    Moore MA; Dorn DC; Schuringa JJ; Chung KY; Morrone G
    Exp Hematol; 2007 Apr; 35(4 Suppl 1):105-16. PubMed ID: 17379095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pathogenic role of insufficiency of polycomb repressive complex in primary myelofibrosis].
    Shinoda D
    Rinsho Ketsueki; 2023; 64(9):998-1006. PubMed ID: 37793876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical impacts of the mutational spectrum in Japanese patients with primary myelofibrosis.
    Morishita S; Ochiai T; Misawa K; Osaga S; Inano T; Fukuda Y; Edahiro Y; Ohsaka A; Araki M; Komatsu N
    Int J Hematol; 2021 Apr; 113(4):500-507. PubMed ID: 33389584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-494-3p overexpression promotes megakaryocytopoiesis in primary myelofibrosis hematopoietic stem/progenitor cells by targeting SOCS6.
    Rontauroli S; Norfo R; Pennucci V; Zini R; Ruberti S; Bianchi E; Salati S; Prudente Z; Rossi C; Rosti V; Guglielmelli P; Barosi G; Vannucchi A; Tagliafico E; Manfredini R
    Oncotarget; 2017 Mar; 8(13):21380-21397. PubMed ID: 28423484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of Ezh2 cooperates with Jak2V617F in the development of myelofibrosis in a mouse model of myeloproliferative neoplasm.
    Yang Y; Akada H; Nath D; Hutchison RE; Mohi G
    Blood; 2016 Jun; 127(26):3410-23. PubMed ID: 27081096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Mutational Profiling of Hematopoietic Progenitor Cells and Circulating Endothelial Cells (CECs) in Patients with Primary Myelofibrosis.
    Farina M; Bernardi S; Polverelli N; D'Adda M; Malagola M; Bosio K; Re F; Almici C; Dunbar A; Levine RL; Russo D
    Cells; 2021 Oct; 10(10):. PubMed ID: 34685741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis.
    Shimizu T; Kubovcakova L; Nienhold R; Zmajkovic J; Meyer SC; Hao-Shen H; Geier F; Dirnhofer S; Guglielmelli P; Vannucchi AM; Feenstra JD; Kralovics R; Orkin SH; Skoda RC
    J Exp Med; 2016 Jul; 213(8):1479-96. PubMed ID: 27401344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations associated with age-related clonal hematopoiesis in PMF patients with rapid progression to myelofibrosis.
    Bartels S; Faisal M; Büsche G; Schlue J; Hasemeier B; Schipper E; Vogtmann J; Westphal L; Lehmann U; Kreipe H
    Leukemia; 2020 May; 34(5):1364-1372. PubMed ID: 31776465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations and prognosis in primary myelofibrosis.
    Vannucchi AM; Lasho TL; Guglielmelli P; Biamonte F; Pardanani A; Pereira A; Finke C; Score J; Gangat N; Mannarelli C; Ketterling RP; Rotunno G; Knudson RA; Susini MC; Laborde RR; Spolverini A; Pancrazzi A; Pieri L; Manfredini R; Tagliafico E; Zini R; Jones A; Zoi K; Reiter A; Duncombe A; Pietra D; Rumi E; Cervantes F; Barosi G; Cazzola M; Cross NC; Tefferi A
    Leukemia; 2013 Sep; 27(9):1861-9. PubMed ID: 23619563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Pathogenesis and Clinical Significance of Driver Mutations in Primary Myelofibrosis: A Review.
    Alshemmari SH; Rajan R; Emadi A
    Med Princ Pract; 2016; 25(6):501-509. PubMed ID: 27756071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.